| Zacks Company Profile for Perrigo Company plc (PRGO : NYSE) |
|
|
| |
| • Company Description |
| Perrigo Co. plc, with a diversified revenue stream, sells infant formulas for the store brand market, generic extended topical prescription (Rx) products and specialty pharmaceutical drugs. It's focusing on self-care products as part of its transformation into a self-care company from a healthcare company. The company divested its Rx segment to Altaris Capital Partners. The company completed its transformation to a consumer self-care company by reconfiguring the portfolio through the divestiture of RX business. Currently, the company has 2 reporting segments. Consumer Self Care Americas (CSCA): The segment comprises the U.S., Mexico and Canada CHC business, including OTC, contract manufacturing, infant formula and animal health categories. Consumer Self Care International?(CSCI): The segment comprises the branded consumer healthcare (BCH) segment mainly in Europe and the company's consumer-focused businesses in the UK and Australia. This segment includes UK liquids licensed products business.
Number of Employees: 8,379 |
|
|
| |
| • Price / Volume Information |
| Yesterday's Closing Price: $13.75 |
Daily Weekly Monthly
 |
| 20 Day Moving Average: 4,395,418 shares |
| Shares Outstanding: 137.62 (millions) |
| Market Capitalization: $1,892.33 (millions) |
| Beta: 0.39 |
| 52 Week High: $30.93 |
| 52 Week Low: $12.17 |
| Short Interest Ratio: |
| |
% Price Change |
% Price Change Relative to S&P 500 |
| 4 Week |
2.46% |
0.69% |
| 12 Week |
-37.92% |
-39.86% |
| Year To Date |
-46.52% |
-54.62% |
|
|
|
|
| |
|
|
| |
| • General Corporate Information |
Officers
Patrick Lockwood-Taylor - Chief Executive Officer and President
Orlando D. Ashford - Chairman
Eduardo Bezerra - Chief Financial Officer
Bradley A. Alford - Director
Julia Brown - Director
|
|
Peer Information
Perrigo Company plc (BJCT)
Perrigo Company plc (CADMQ)
Perrigo Company plc (APNO)
Perrigo Company plc (UPDC)
Perrigo Company plc (IMTIQ)
Perrigo Company plc (CYGN)
|
|
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED PRODUCTS
Sector: Medical
CUSIP: G97822103
SIC: 2834
|
|
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 09/01/25
Next Expected EPS Date: 02/26/26
|
|
Share - Related Items
Shares Outstanding: 137.62
Most Recent Split Date: 8.00 (2.00:1)
Beta: 0.39
Market Capitalization: $1,892.33 (millions)
|
|
|
|
|
| |
| • EPS Information |
• Dividend Information |
| Analyst Coverage: No |
Dividend Yield: 8.44% |
| Current Fiscal Quarter EPS Consensus Estimate: $0.78 |
Indicated Annual Dividend: $1.16 |
| Current Fiscal Year EPS Consensus Estimate: $2.76 |
Payout Ratio: 0.40 |
| Number of Estimates in the Fiscal Year Consensus: 2.00 |
Change In Payout Ratio: -0.04 |
| Estmated Long-Term EPS Growth Rate: % |
Last Dividend Paid: 11/28/2025 - $0.29 |
| Next EPS Report Date: 02/26/26 |
|
|
|
| |
